Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):173–178. doi: 10.1128/aac.40.1.173

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.

J Gavaldà 1, P J Cardona 1, B Almirante 1, J A Capdevila 1, M Laguarda 1, L Pou 1, E Crespo 1, C Pigrau 1, A Pahissa 1
PMCID: PMC163078  PMID: 8787901

Abstract

We compared the efficacy of ampicillin, both alone and in combination with gentamicin given once a day (q.d.) or three times a day (t.i.d.), in the treatment of experimental enterococcal endocarditis. Ampicillin was administered by using humanlike pharmacokinetics that simulated the profiles of this drug in human serum. An open one-compartment mathematical model developed in this study was used to estimate the decreasing doses administered with a computer-controlled infusion pump that simulated in rabbits the human serum pharmacokinetics after intravenous administration of 2 g of ampicillin every 4 h. Animals with catheter-induced endocarditis were infected intravenously with 10(8) CFU of Enterococcus faecalis J4 (MICs and MBCs of ampicillin and gentamicin, 2 and 128 and 16 and 64 micrograms/ml, respectively) and were treated for 3 days with ampicillin alone or in combination with gentamicin at 2 mg/kg of body weight subcutaneously t.i.d. or at 6 mg/kg subcutaneously q.d. The serum ampicillin levels and pharmacokinetic parameters of the humanlike pharmacokinetics of ampicillin in rabbits were similar to those found in humans treated with 2 g of ampicillin intravenously. The results of therapy for experimental endocarditis caused by E. faecalis J4 showed that the residual bacterial concentration in aortic valve vegetation was significantly lower in the animals treated with combinations of ampicillin plus gentamicin given q.d. or t.i.d. than in those treated with ampicillin alone (P < 0.01). The dosing interval of gentamicin did not significantly affect (q.d. versus t.i.d.; P = 0.673) the therapeutic efficacy of the combination of ampicillin plus gentamicin.

Full Text

The Full Text of this article is available as a PDF (233.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bamonte F., Dionisotti S., Gamba M., Ongini E., Arpini A., Melone G. Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy. 1990;36(1):41–50. doi: 10.1159/000238747. [DOI] [PubMed] [Google Scholar]
  2. Bisno A. L., Dismukes W. E., Durack D. T., Kaplan E. L., Karchmer A. W., Kaye D., Rahimtoola S. H., Sande M. A., Sanford J. P., Watanakunakorn C. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA. 1989 Mar 10;261(10):1471–1477. [PubMed] [Google Scholar]
  3. Blatter M., Fluckiger U., Entenza J., Glauser M. P., Francioli P. Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother. 1993 Sep;37(9):1971–1976. doi: 10.1128/aac.37.9.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crémieux A. C., Saleh-Mghir A., Vallois J. M., Muffat-Joly M., Devine C., Pocidalo J. J., Carbon C. Influence of the pre-treatment duration of infection on the efficacies of various antibiotic regimens in experimental streptococcal endocarditis. J Antimicrob Chemother. 1993 Dec;32(6):843–852. doi: 10.1093/jac/32.6.843. [DOI] [PubMed] [Google Scholar]
  5. Durack D. T., Beeson P. B. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol. 1972 Feb;53(1):44–49. [PMC free article] [PubMed] [Google Scholar]
  6. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother. 1990 Dec;34(12):2387–2391. doi: 10.1128/aac.34.12.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fluckiger U., Moreillon P., Blaser J., Bickle M., Glauser M. P., Francioli P. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob Agents Chemother. 1994 Dec;38(12):2846–2849. doi: 10.1128/aac.38.12.2846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flückiger U., Segessenmann C., Gerber A. U. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991 Sep;35(9):1905–1910. doi: 10.1128/aac.35.9.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fuursted K. Evaluation of the combination effects of ampicillin or vancomycin combined with streptomycin, gentamicin, tobramycin or netilmicin against enterococci. APMIS. 1989 Jan;97(1):23–26. doi: 10.1111/j.1699-0463.1989.tb00749.x. [DOI] [PubMed] [Google Scholar]
  10. Garrison P. K., Freedman L. R. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med. 1970 Jun;42(6):394–410. [PMC free article] [PubMed] [Google Scholar]
  11. Gavaldà J., Pahissa A., Almirante B., Laguarda M., Crespo E., Pou L., Fernández F. Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Antimicrob Agents Chemother. 1995 Sep;39(9):2098–2103. doi: 10.1128/aac.39.9.2098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  13. Gerber A. U., Kozak S., Segessenmann C., Flückiger U., Bangerter T., Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):233–237. doi: 10.1007/BF01965266. [DOI] [PubMed] [Google Scholar]
  14. Gerber A. U., Stritzko T., Segessenmann C., Stalder B. Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model. Scand J Infect Dis Suppl. 1990;74:195–203. [PubMed] [Google Scholar]
  15. Hessen M. T., Pitsakis P. G., Levison M. E. Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo. Antimicrob Agents Chemother. 1989 May;33(5):608–611. doi: 10.1128/aac.33.5.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  17. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  18. Maller R., Ahrne H., Eilard T., Eriksson I., Lausen I. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother. 1991 May;27 (Suppl 100):121–128. doi: 10.1093/jac/27.suppl_c.121. [DOI] [PubMed] [Google Scholar]
  19. Mizen L., Woodnutt G., Kernutt I., Catherall E. J. Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis. Antimicrob Agents Chemother. 1989 May;33(5):693–699. doi: 10.1128/aac.33.5.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Norrby S. R., O'Reilly T., Zak O. Efficacy of antimicrobial agent treatment in relation to treatment regimen: experimental models and clinical evaluation. J Antimicrob Chemother. 1993 May;31 (Suppl 500):41–54. doi: 10.1093/jac/31.suppl_d.41. [DOI] [PubMed] [Google Scholar]
  21. Olier B., Viotte G., Morin J. P., Fillastre J. P. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Chemotherapy. 1983;29(6):385–394. doi: 10.1159/000238225. [DOI] [PubMed] [Google Scholar]
  22. Perlman B. B., Freedman L. R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971 Oct;44(2):206–213. [PMC free article] [PubMed] [Google Scholar]
  23. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar]
  24. Saleh-Mghir A., Cremieux A. C., Vallois J. M., Muffat-Joly M., Devine C., Carbon C. Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis. Antimicrob Agents Chemother. 1992 Nov;36(11):2403–2407. doi: 10.1128/aac.36.11.2403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  26. Tulkens P. M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother. 1991 May;27 (Suppl 100):49–61. doi: 10.1093/jac/27.suppl_c.49. [DOI] [PubMed] [Google Scholar]
  27. Wood C. A., Norton D. R., Kohlhepp S. J., Kohnen P. W., Porter G. A., Houghton D. C., Brummett R. E., Bennett W. M., Gilbert D. N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988 Jul;158(1):13–22. doi: 10.1093/infdis/158.1.13. [DOI] [PubMed] [Google Scholar]
  28. Woodnutt G., Berry V., Mizen L. Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections. Antimicrob Agents Chemother. 1992 Jul;36(7):1427–1431. doi: 10.1128/aac.36.7.1427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Woodnutt G., Catherall E. J., Kernutt I., Mizen L. Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum. Antimicrob Agents Chemother. 1988 Nov;32(11):1705–1709. doi: 10.1128/aac.32.11.1705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES